Should Tamiflu™ be stockpiled locally?


  • Sandro Cinti, MD
  • Gerald Blackburn, DO



pandemic, influenza, oseltamivir, Tamiflu™, antivirals, first responders


The outbreak of H5N1 avian influenza in Asia raises serious concerns about an influenza pandemic of the kind seen in 1918. In addition, the recent federal response to Hurricane Katrina highlights the need for advanced local preparation for biological disasters. It is clear that there will not be enough vaccine early in an influenza pandemic. Without vaccine, the role of antivirals, especially oseltamivir (Tamiflu™), in treatment and prophylaxis becomes of paramount importance. It is unlikely that the Centers for Disease Control and Prevention (CDC) will be able to stockpile enough oseltamivir to protect every first responder in the United States. Thus, it is important that local governments and hospitals consider stockpiling oseltamivir for the treatment and/or prophylaxis of local first responders.

Author Biographies

Sandro Cinti, MD

Clinical Assistant Professor, Infectious Diseases, University of Michigan Hospitals/Ann Arbor VA Health Systems, Ann Arbor, Michigan; National Center for Critical Incident Analysis (NCCIA), National Defense University, Washington DC.

Gerald Blackburn, DO

Botsford Hospital, Farmington Hills; Michigan State University College of Osteopathic Medicine, Michigan.


Crosby A: America’s Forgotten Pandemic. Cambridge: Cambridge University Press, 1989.

World Health Organization: Cumulative number of confirmed human cases of avian influenza A (H5N1) since 28 January 2004. World Health Organization Web site. Available at Accessed April 12, 2006.

Schoch-Spana M: Implications of pandemic influenza for bioterrorism response. Clin Infect Dis. 2000; 31: 1409-1413.

Meltzer ML, Cox NJ, Fukuda K: The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg Infect Dis. 1999; 5: 659-672.

Hsu S: Brown defends FEMA’s efforts. The Washington Post. September 28, 2005; A01.

The World Health Organization. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Global Health Security: Epidemic Alert and Response. 2004:1-11.

Patriarca PA, Cox NJ: Influenza pandemic preparedness plan for the United States. J Infect Dis. 1997; 176(suppl. 1): S4-S7.

Stohr K, Esveld M: Public Health: Enhanced: Will vaccines be available for the next influenza pandemic? Science. 2004; 306: 2195-2196.

Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2003; 52(RR-08): 1-50.

Taubenberger JK, Reid AH, Fanning TG: Capturing a killer flu virus. Sci Am. 2005; 292: 48-57.

Moser MR, Bender TR, Margolis HS, et al.: An outbreak of influenza aboard a commercial airliner. Am J Epidemiol. 1979; 110: 1-6.

Salgado CD, Farr BM, Hall KK, et al.: Influenza in the acute hospital setting. Lancet Infect Dis. 2002; 2: 145-155.

Peiris JSM, Chu CM, Cheng VCC, et al.: Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet. 2003; 361: 1519-1520.

Gopalakrishna G, Choo P, Leo YS, et al.: SARS transmission and hospital containment. Emerg Infect Dis. 2004; 10: 395-400.

Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al.: Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005; 11: 201-208.

Hien TT, Liem NT, Dung NT, et al.: Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004; 350: 1179-1188.

CDC Guidelines and Recommendations: Influenza antiviral medications; 2005-2006 chemoprophylaxis (prevention) and treatment guidelines.

Wainright PO, Perdue ML, Brugh M, et al.: Amantadine resistance among hemagglutinin subtype 5 strains of avian influenza virus. Avian Dis. 1991; 35: 31-39.

Saito R, Oshitani H, Masuda H, et al.: Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol. 2002; 40: 84-88.

Ward P, Smith I, Small J, et al.: Oseltamivir (Tamiflu™) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005; 55 (suppl. S1): i5-i21.

Brady MT, Sears SD, Pacini DL, et al.: Safety and prophylactic efficacy of low-dose rimantidine in adults during an influenza A epidemic. Antimicrob Agents Chemother. 1990; 34: 1633-1636.

Shilling M, Povinelli L, Krause P, et al.: Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 1998; 16: 1771-1774.

Hayden FG, Altmar RL, Schilling M, et al.: Use of the selective neuraminidase inhibitor oseltamivir to prevent influenza. New Engl J Med. 1999; 341: 1336-1343.

Bowles SK, Lee W, Simor AE, et al.: Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002; 50: 608-616.

Longini IM, Halloran ME, Nizam A: Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004; 159: 623- 633.

Hayden FG: Pandemic influenza: Is an antiviral response realistic? Pediatr Infect Dis J. 2004; 23: S262-S269.

Kaiser L, Wat C, Mills T, et al.: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003; 163: 1667-1672.

Whitley RJ, Hayden FG, Reisinger KS, et al.: Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20: 127-133.

HHS Pandemic Flu Plan, November 2005. United States Department of Health and Human Services Web site. Available at Accessed April 12, 2006.